Replimune Group, Inc. (REPL) balance sheet
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.81+0.12 (+0.61%)
Close on Nov 18, 2026Market cap $1.88BP/E –Yield –
Replimune Group, Inc. balance sheet
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2026
- -107.9%
Financial strength
- Current ratio
- 7.11
- Debt to equity
- 0.49
- Debt to assets
- 26.7%
- Cash to current liabilities
- 675.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.17
- Dividend yield
- –
See a number that looks wrong?